Uniqure NV (QURE) is a Healthcare · Biotechnology company listed on NASDAQ. Price $43.99 (-0.23%), Market cap $1.56B, 52-week low–high $9.03 ~ $70.59.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which
Financial statements, price targets, institutional (13F) holdings and related news for Uniqure NV are updated in real time on BlackAll Trade.
Uniqure NV trades at $43.99 (-0.23%). Real-time quotes and charts are available on BlackAll Trade.
Uniqure NV has a market cap of about $1.56B.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produc